Our findings indicate that inhibition of Rac1 activation by the compound 1A-116 reverses 5-FU resistance in CRC cells, decreases tumor growth, and prevents metastasis development, suggesting a therapeutic application of 1A-116 for the treatment of therapy-resistant CRC. Here, RAC1 is linked to colorectal carcinoma.